Clinical Trial Update: A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases [Phase 1]

View source ↗

Summary

Century Therapeutics’ CNTY-101 is being evaluated in a Phase 1 study for refractory B cell–mediated autoimmune diseases, with the trial currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Idiopathic Inflammatory Myopathies
• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• CNTY-101

Snippet

Sponsor: Century Therapeutics, Inc. | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Status: ACTIVE_NOT_RECRUITING